Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: RETRACTED ARTICLE: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK–Mfn2 signaling pathway

Fig. 2

HepG2 cells proliferation and migration are modulated by LATS2 overexpression in the presence of sorafenib. a, b EdU staining was used to observe cell proliferation. The number of EdU-positive cells was recorded. Adenovirus-loaded LATS2 was transfected into HepG2 cells in the presence of sorafenib. c–e Western blotting was performed to analyze the protein expression of cyclin factors in HepG2 cells. Adenovirus-loaded LATS2 was transfected into HepG2 cells in the presence of sorafenib. f, g Transwell assay was used to detect the mobilization of HepG2 cells. The number of migrated cells was recorded. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. h RNA was isolated from HepG2 cells after exposure to sorafenib and then the transcription of CXCR4/CXCR7 was evaluated via qPCR. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us